Web Analytics

Our publications:
Our publications

Ma Yunyan

Senior Partner
Sundial Law Firm

Tel: +86 755 8826 5120
Email: yunyanma@shujin.cn

Practice areas

Capital markets; Corporate & commercial; Private equity, venture capital & funds; Dispute resolution


Ma Yunyan, senior partner at Sundial Law Firm, graduated from the Law Department of Peking University in 1984. She joined Sundial in 1994, specialising in mergers and acquisitions, securities issuance in the capital markets, etc. She was employed as a member of the Listing Committee of the Shenzhen Stock Exchange, a member of the first and second GEM Issuance Review Committees of the China Securities Regulatory Commission, a member of the first Municipal Committee of the Shenzhen Stock Exchange under the registration system. She is currently an arbitrator of the Shenzhen Court of International Arbitration.

Ma has been practising law for about 30 years, focusing on the capital markets business, and has extensive experience in issuing stocks and bonds and mergers and acquisitions at home and abroad. She has been well-received by clients and has been rated as one of China’s outstanding lawyers by well-known international and domestic rating agencies many times. Some representative projects Ma handled include: Wisesoft, Das Intellitech, SUNWODA, Hybribio Biotech, FRD Science & Technology, CIMC Vehicles, Kawin Technology, Mehow and other IPOs and A-share listings.

Ma also managed the IPO of AAC Technologies on the main board of the Hong Kong stock exchange. Vanke’s B-to-H share listing on Hong Kong’s main board; Ningbo Shanshan share spin-off of FY Financial and FIRS to the H-share listing project, CIMC Group’s spin-off of CIMC Vehicle to the H-share listing project, and the Huaxin Cement B shares to H shares project. Among them, the Huaxin Cement’s project was rated as the 15th Most Creative Project of New Fortune, and recognised in Deals of the Year 2022 by China Business Law Journal.

Ma also invested in Silkroad Visual on behalf of the China Culture Industry Fund; and participated in the restructuring of BGI’s infection prevention and control business sector on behalf of Songhe International Capital. Ma assisted the listed company Boya-Bio tointroduce China Resources Pharmaceutical as a controlling stakeholder. This project, as well as the domestic listing of CIMC Vehicle, were both awarded the 15th Most Creative Project of New Fortune, and recognised in Deals of the Year 2021 by China Business Law Journal.

Tell others about this lawyer
Copy link

Join our mailing list for legal news and alerts

Sign up